Brain Stimulation 2015
DOI: 10.1002/9781118568323.ch17
|View full text |Cite
|
Sign up to set email alerts
|

Vagus Nerve Stimulation for Epilepsy and Depression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 186 publications
0
8
0
Order By: Relevance
“…These newer non-invasive VNS delivery systems do not require surgery, and permit patient-administered stimulation on demand; therefore, they improve the safety and tolerability of VNS, making it more accessible and facilitating further investigations across a wider range of uses [55]. VNS has now obtained approval by the US Food and Drug Administration and EU regulatory agencies for [56], and treatment-resistant depression [57]. In particular, non-invasive VNS has gained popularity for its ease of use, broad spectrum of efficacy and tolerability in extremes of age and mental capacity [58].…”
Section: Vagus Nerve Stimulationmentioning
confidence: 99%
“…These newer non-invasive VNS delivery systems do not require surgery, and permit patient-administered stimulation on demand; therefore, they improve the safety and tolerability of VNS, making it more accessible and facilitating further investigations across a wider range of uses [55]. VNS has now obtained approval by the US Food and Drug Administration and EU regulatory agencies for [56], and treatment-resistant depression [57]. In particular, non-invasive VNS has gained popularity for its ease of use, broad spectrum of efficacy and tolerability in extremes of age and mental capacity [58].…”
Section: Vagus Nerve Stimulationmentioning
confidence: 99%
“…Vagus nerve stimulation (VNS) has assumed an increasingly important role in the nonpharmacologic management of medically refractory seizures . The VNS system used in this study has been employed to treat >65,000 patients with epilepsy worldwide …”
mentioning
confidence: 99%
“…These newer non-invasive VNS delivery systems do not require surgery, and permit patient-administered stimulation on demand; therefore, they improve the safety and tolerability of VNS, making it more accessible and facilitating further investigations across a wider range of uses [55]. VNS has now obtained approval by the US Food and Drug Administration and EU regulatory agencies for treatment-resistant partial onset seizure disorder [56], and treatment-resistant depression [57]. In particular, non-invasive VNS has gained popularity for its ease of use, broad spectrum of efficacy and tolerability in extremes of age and mental capacity [58].…”
Section: Vagus Nerve Stimulationmentioning
confidence: 99%